Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Senti Biosciences Holdings, Inc.SNTI · Entity 7935 | Chief Financial Officer · Head of Corporate Development | February 01, 2024 | February 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Senti Biosciences Holdings, Inc.
Report date February 01, 2024 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 131,000 |
Reported balance
After 2024-02-01 transaction · row 1
1 source rowRow 1 · 2024-02-01 · Grant · Acquired 101,000 · Balance 131,000 F1: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2034-01-31 | Direct | 152,000 |
Reported balance
After 2024-02-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-01 · Grant · Acquired 152,000 · Balance 152,000 F2: The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.
F2: The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kronos Bio, Inc.
Report date June 20, 2025 · Filed June 20, 2025
Section 16 reporting ended · disclosed 2025-06-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 1
1 source rowRow 1 · 2025-06-20 · Other · Disposed 139,422 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2034-06-02 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-20 · Disposition to issuer · Disposed 246,390 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]
F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.
F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2025 Filed Jun 20, 2025 16:15 UTC | Kronos Bio, Inc. KRON · Entity 78257 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 246,390 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001415889-25-017823 · form4-06202025_040601.xml · derivative · entry 2 KNOBELMAN DEBORAH · CIK 0001931509 · President & Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 246,390 shares Expires 2034-06-02 F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 16:15 UTC | Kronos Bio, Inc. KRON · Entity 78257 | OtherCommon Stock | 139,422 | $0.57 | $79,470.54 |
DisclosureSEC source: 0001415889-25-017823 · form4-06202025_040601.xml · nonDerivative · entry 1 KNOBELMAN DEBORAH · CIK 0001931509 · President & Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2 · shares: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 16:47 UTC | Kronos Bio, Inc. KRON · Entity 78257 | SaleCommon Stock | 24,838 | $0.87 | $21,554.42 |
DisclosureSEC source: 0001415889-25-016003 · form4-06062025_080640.xml · nonDerivative · entry 1 KNOBELMAN DEBORAH · CIK 0001931509 · President & Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,422 F1 · shares: Represents shares sold to satisfy estimated tax withholding obligations upon the settlement of restricted stock units. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 17:02 UTC | Kronos Bio, Inc. KRON · Entity 78257 | GrantEmployee Stock Option (Right to Buy) · Derivative | 246,390 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001415889-24-015398 · form4-06042024_090603.xml · derivative · entry 2 KNOBELMAN DEBORAH · CIK 0001931509 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,390 Underlying: Common Stock · 246,390 shares Expires 2034-06-02 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on June 3, 2025 and the remaining shares shall vest in 36 equal monthly installments as of the last calendar day of each month thereafter. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 17:02 UTC | Kronos Bio, Inc. KRON · Entity 78257 | GrantCommon Stock | 164,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015398 · form4-06042024_090603.xml · nonDerivative · entry 1 KNOBELMAN DEBORAH · CIK 0001931509 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,260 Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 22:24 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 152,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001854270-24-000013 · wk-form4_1706912660.xml · derivative · entry 2 KNOBELMAN DEBORAH · CIK 0001931509 · Chief Financial Officer · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,000 Underlying: Common Stock · 152,000 shares Expires 2034-01-31 F2 · derivative.exercise_date: The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 22:24 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantCommon Stock | 101,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001854270-24-000013 · wk-form4_1706912660.xml · nonDerivative · entry 1 KNOBELMAN DEBORAH · CIK 0001931509 · Chief Financial Officer · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,000 F1 · shares: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:20 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001854270-23-000019 · wf-form4_167537644193252.xml · derivative · entry 1 KNOBELMAN DEBORAH · CIK 0001931509 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 20:47 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001854270-22-000036 · wf-form4_166491640953549.xml · derivative · entry 2 KNOBELMAN DEBORAH · CIK 0001931509 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2032-10-02 F2 · derivative.exercise_date: 25% of the shares underlying this option vest on September 20, 2023 and the remainder vest in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 20:47 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001854270-22-000036 · wf-form4_166491640953549.xml · nonDerivative · entry 1 KNOBELMAN DEBORAH · CIK 0001931509 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award will vest on September 20, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.